Patients must not have received any chemotherapy within 14 days prior to registration
Patients with cervix cancer who have received any previous radiation or chemotherapy
Patients who have received any chemotherapy (excluding steroids) and/or RT prior to this enrollment
Patients who have received prior chemotherapy or radiation therapy are not eligible
Patients may have received prior hormone therapy and/or systemic chemotherapy; such therapy must have been completed at least 6 months prior to study entry and the patient has clear evidence of disease subsequent to such therapy; patients must not have received neoadjuvant chemotherapy for the present recurrent disease
Patients who received chemotherapy directed at the present recurrence
Patients who have received any previous chemotherapy or radiation therapy are not eligible
Patients must not have received any prior chemotherapy, radiation therapy, or other therapy for the treatment of ALL (other than those noted below) and must not be receiving any immunosuppressive therapy; patients may not have received any prior investigational therapy within 28 days prior to registration; patients must not have received any monoclonal antibody therapy within 42 days of registration; patients may have received the following within any time prior to registration: low dose chemotherapy-including: cyclophosphamide 1 g/m^2, oral 6-mercaptopurine, or oral methotrexate (other low dose chemotherapy may be allowable, however any other options not listed here should be confirmed with the study chairs), TKI therapy, steroids, hydroxyurea, leukapheresis, intrathecal chemotherapy or vincristine (vincristine sulfate)
Multiple myeloma: must have received prior chemotherapy; consolidation of chemotherapy by autografting prior to nonmyeloablative HCT is permitted
Patients who received chemotherapy (including monoclonal antibodies) or radiotherapy, administered for any condition, within 4 weeks prior to registration are not eligible
Patients must have received some immunosuppressive chemotherapy in the preceding 3 months.
Patients who have received prior radiation or chemotherapy may be enrolled on this study
Patients may not have received prior systemic treatment (chemotherapy or targeted therapy) for advanced BTC; prior adjuvant chemotherapy is permitted provided it was completed > 6 months from registration
Subject has received prior radiation therapy or chemotherapy for prostate cancer
Prior systemic chemotherapy or radiation therapy for transitional cell carcinoma of the bladder\r\n* Subjects who have received prior intravesical chemotherapy are allowed
Prior chemotherapy or tumor vaccine therapy or biological therapy for the treatment of melanoma. Subjects who received chemotherapy for the management of other malignancies are potentially eligible if the subject has not received chemotherapy in prior 5 years, remained disease free, and following discussion with and agreement by the principal investigator
Patients receiving concomitant chemotherapy administration in the 5 days preceding brachytherapy (except for gynecological cancer patients who may have received concurrent chemotherapy as a component of their treatment regimen)
Subjects must not have received chemotherapy within 2 weeks of planned first (1st) day of radiation therapy (RT)
Patients can have had any number of prior therapies, however must have had previous therapy with at least radiotherapy; patients with oligodendroglioma must have also received chemotherapy in addition to radiation therapy
Multiple myeloma – must have received prior chemotherapy; consolidation of chemotherapy by autografting prior to nonmyeloablative HCT is permitted
Patients can either be chemotherapy-naive or have received platinum-based chemotherapy for locally advanced or metastatic disease; acute effects of therapy must have resolved to baseline severity or to CTCAE grade =< 1 except for AEs that in the investigator’s judgment do not constitute a safety risk for the patient; patients who have received prior treatment with checkpoint inhibitors are eligible
STUDY TREATMENT: Patients must have received systemic radiosensitizing chemotherapy with definitive pelvic radiation therapy; patients may have received partial amount of chemotherapy and radiation (both) to be eligible
Patients must have received standard of care therapy with chemoradiation with temozolomide followed by adjuvant chemotherapy with temozolomide. Patients may have received one additional chemotherapy regimen (other than lomustine) in addition to adjuvant temozolomide prior to study entry (patients at either first or second recurrence are eligible).
Received more than 1 prior systemic chemotherapy in the unresectable or metastatic setting; if the patient received 1 prior systemic chemotherapy, the patient is eligible; having received prior therapies for breast cancer (such as everolimus or experimental agents) does not affect eligibility for this study
Patients must have a histologically confirmed solid tumor that is surgically resected and have completed all planned adjuvant therapy or are not planned for any adjuvant therapy (including hormonal); patients must have fully recovered from surgery (i.e. sutures and drains have been removed); patients must have recovered from toxicity of prior chemotherapy and/or radiotherapy; patients may not have received chemotherapy in the prior four weeks; patients may have not received radiotherapy in the prior three weeks
Patients who have received prior radiation or chemotherapy may be enrolled on this study
Patients must have not have received any prior therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) for the treatment of stage IV NSCLC; patients may have received prior adjuvant or neoadjuvant chemotherapy or chemotherapy given as part of a curative intent chemoradiotherapy approach for NSCLC, if the last administration of the prior regimens occurred at least 1 year prior to study entry
BC patients with a previous history of another cancer who have NOT received any chemotherapy or chemotherapy and radiation, but have only received surgical treatments are eligible;
Patients who have received prior chemotherapy
Patients who received previous anti-folate-containing chemotherapy
PRIOR TO LYMPHODEPLETION: Received chemotherapy within the previous 3 weeks prior to lymphodepletion
Patients may have received prior systemic chemotherapy; such therapy must have been completed at least 5 years prior to study entry and the patient has no evidence of disease subsequent to such therapy; patients must not have received neoadjuvant chemotherapy for the present disease
Patients who received chemotherapy directed at the present disease
Patients who have received chemotherapy and/or radiation therapy within 2 weeks unless there is evidence of rapidly progressive disease; in the event that subjects have received chemotherapy < 2 weeks from the date of enrollment, they may be included provided they have recovered from the associated non-hematological toxicities to less than or equal to grade 1; hydroxyurea is allowed up to 24 hours prior to starting therapy in the setting of rapidly proliferating disease
Patients must not have received any systemic chemotherapy for advanced biliary cancer
Subject has received chemotherapy within the last 4 weeks prior to first treatment.
Patients who have received prior chemotherapy for endometrial cancer.
Has not received chemotherapy in the last 28 days
Patients who have received systemic chemotherapy or radiotherapy within two months prior to first scheduled cycle of postoperative chemotherapy
Patients must have received prior induction chemotherapy for at least 2 months and up to 6 months; at least three weeks should have elapsed after the last chemotherapy
Any prior adjuvant cytotoxic chemotherapy within 12 months of registration; subjects who received chemotherapy for earlier stage disease more than 12 months prior to study registration are eligible for this trial
Patients must not have received systemic chemotherapy for at least 4 weeks, and must not have received prior radiation therapy to the tumor site being irradiated on this study
Patients who have received prior chemotherapy (including Gliadel wafers) for the current glioma
Patients who have not completed standard of care treatment prior to participation in this trial, i.e. surgical procedure and radiation therapy (at least 59 Gy); Note: If tumor is unmethylated, patients are not mandated to have received chemotherapy prior to participation in this trial; however, if tumor is methylated, patients must have received at least one chemotherapy regimen prior to participation in this trial
Patients who have received prior chemotherapy
If a cancer survivor, the patient received prior systemic chemotherapy or radiotherapy
Subjects who have received chemotherapy within 12 months prior to randomization
Either:\r\n* Patients who have received radiation therapy (RT): Previously (>= 6 months before to enrollment) completed treatment for pancreatic or periampullary adenocarcinoma consisting of either surgical resection with neoadjuvant/adjuvant conventional conformal radiation therapy (CRT) for resectable disease or conventional CRT as definitive treatment for unresectable disease; these patients who have received prior radiation therapy will constitute Cohort A and will receive SBRT as 5 Gy x 5; patients may be receiving continued chemotherapy post initial CRT; OR\r\n* Patients who have not received RT: Previously (>= 3 months before retreatment) initiated treatment for pancreatic or periampullary adenocarcinoma consisting of chemotherapy alone for unresectable disease or surgical resection with neoadjuvant/adjuvant chemotherapy for resectable disease; these patients who have not received prior radiation therapy will constitute Cohort B and will receive SBRT as 6.6 Gy x 5; patients must have attempted chemotherapy upon initial diagnosis
Patients with cervix cancer who have received any previous radiation or chemotherapy
Patients enrolled in Strata A and B may not have received any prior chemotherapy or anti-glioma therapy of any type other than radiation therapy; patients enrolled on Stratum C must have received at least two prior chemotherapy or biologic therapy regimens and may not have received radiation to the index lesion within 1 year of enrollment; patients on Strata A, B, E, and F cannot have received chemotherapy after radiation therapy was completed
Patients may have received prior chemotherapy
Stage I: subjects may have already received no more than 2 cycle of their platinum-based chemotherapy but should not have received other prior chemotherapy regimens with the exception of patients with metastatic disease who received neoadjuvant or adjuvant chemotherapy and that chemotherapy was completed > 6 months prior to enrollment
Multiple myeloma: Must have received prior chemotherapy; consolidation of chemotherapy by autografting prior to nonmyeloablative hematopoietic cell transplant (HCT) is permitted
Patients must not have received any other anti-cancer treatment (including surgery, radiation or systemic chemotherapy) since the base trial.
Patients who have received standard chemotherapy with FDA approved agents within 21 days of entry into the protocol.
Received chemotherapy drugs within previous 2 weeks
Participants who have received any chemotherapy or radiotherapy for previous malignancy are not eligible
Patients are not eligible who have received systemic chemotherapy or investigational agents =< 28 days prior to registration
Patients must have received prior treatment with chemotherapy. Chemotherapy may have previously been given with a PD-1 or PDL-1 inhibitor.
Patients who have received previous chemotherapy or radiation therapy (does NOT include steroids)
Patients must not have received prior chemotherapy, radiotherapy, or antibody therapy for lymphoma
Patients may have received no prior chemotherapy for stage IV disease; patients may have received prior adjuvant therapy (chemotherapy and/or chemoradiation) if more than 6 months have elapsed between the end of adjuvant therapy and registration
Patients who have received any radiotherapy or chemotherapy for their current gynecological cancer
Patients must NOT have received prior chemotherapy or targeted therapy, including chemotherapy used for radiation sensitization for treatment of endometrial carcinoma
Patient has received systemic chemotherapy =< 3 weeks prior to registration
Patients in the relapsed/refractory AML cohort (Cohort 2), must meet all of the following criteria:\r\n* Patient must have received at least one prior Induction chemotherapy regimen for their AML;\r\n** They may have received any type of chemotherapy\r\n** Administration of hydroxyurea to control high white blood cells (WBC) prior to, during, and after registration is permitted\r\n* Relapse or refractory disease must be documented by a bone marrow examination demonstrating > 5% blasts in the bone marrow not attributable to another cause\r\n* Patient must NOT have received chemotherapy within 14 days prior to registration
Subject must have received at least 6 months of chemotherapy
Patients who received prior systemic chemotherapy for the study cancer.
Patients on the Phase I portion may not have received ANY prior chemotherapy; patients on the Phase II portion may have received one prior cycle of any non-investigational chemotherapy; prior chemotherapy must have been completed within 56 days prior to registration and all toxicities must have resolved to =< grade 1; patients on either portion may have received prior treatment with dexamethasone, providing total number of days of treatment was =< 14 days and total treatment dose was =< 360 mg
Have received previous chemotherapy for advanced NSCLC. Participants who have received adjuvant or neoadjuvant chemotherapy are eligible if the last administration of the prior regimens occurred at least 1 year prior to study entry.
Subjects who have received any systemic chemotherapy, including anti-VEGF therapy, or any systemic investigational anticancer agents, including lenvatinib, for advanced/unresectable HCC. Note: Subjects who have received local hepatic injection chemotherapy are eligible.
Patients may not have received more than one prior chemotherapy
Patients who have received any prior chemotherapy are not eligible
May not have received prior chemotherapy; if patient has received prior adjuvant therapy, must be > 6 months from treatment
Patients who have received prior chemotherapy for any abdominal or pelvic tumor are excluded; patients who have received neoadjuvant chemotherapy prior to their initial debulking are excluded; patients may have received prior adjuvant chemotherapy for breast cancer
Patients who have received prior chemotherapy (including Gliadel wafers) for the current glioma
Patients who received chemotherapy directed at the present disease
Patients who have received previous chemotherapy or radiation therapy to treat the current disease
Currently receiving any chemotherapy, investigational agents or registration on another therapy based trial or received chemotherapy with radiation therapy (e.g., temozolomide)
Patients who have received prior radiation or chemotherapy may be enrolled on this study
Patients who received investigational chemotherapy prior to radiation therapy are excluded from this study
Patients who have received prior treatment with implanted radiotherapy or chemotherapy sources such as wafers of polifeprosan 20 with carmustine
Subject may have received chemotherapy or other therapy after harvest of tumor and prior to enrollment; subjects who have achieved complete response following chemotherapy are still eligible for participation
Patients may have received no prior chemotherapy for stage IV disease; patients may have received prior adjuvant therapy (chemotherapy and/or chemoradiation) if more than 6 months have elapsed between the end of adjuvant therapy and registration
Patients who have received prior chemotherapy for their original breast cancer treatment are still eligible
Multiple myeloma or plasma cell leukemia must have received more than one line of prior chemotherapy; consolidation of chemotherapy by autografting prior to nonmyeloablative HCT is permitted
Patients may have received no prior chemotherapy for metastatic or unresectable disease; patients may have received prior adjuvant therapy (chemotherapy and/or chemoradiation) if more than 6 months have elapsed between the end of adjuvant therapy and registration; patients may not have received prior docetaxel or cisplatin
Prior chemotherapy, radiation for any malignancy in which they received any thoracic radiotherapy
5. Received last dose of prior chemotherapy within ? 6 weeks of first dose of VS-6063.
Patients who have received chemotherapy within 7 days prior to the cryoablation procedure
Patient must not have received prior chemotherapy or radiation for pancreatic cancer and no exposure to systemic chemotherapy
Patients must have completed at least 1 prior line of chemotherapy for germ cell tumor (except patients who present with primary pure teratoma who need not have received any previous chemotherapy)
For patients who received prior adjuvant chemotherapy or chemoradiotherapy: a treatment-free interval of at least 12 months since last chemotherapy or chemoradiotherapy cycle
Patients must be pemetrexed-naïve; patients may have received any number of prior chemotherapy or molecularly targeted agents; if crizotinib was used in the first (1st) line setting then chemotherapy naive patients are also eligible; if patient received crizotinib in combination with chemotherapy, prior chemotherapy must have been discontinued at least 14 days prior to registration and all adverse events must have resolved to =< grade 1
Prior chemotherapy is allowed if >= one month from the end of treatment; patients must not have received chemotherapy within 4 weeks of the start of study drug
Received radiotherapy and temozolomide chemotherapy
All patients must have received at least one standard chemotherapy or chemoradiotherapy
Has received previous chemotherapy for Stage IV NSCLC (participants who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 6 months prior to randomization)
Prior systemic chemotherapy for transitional cell carcinoma of the bladder; subjects who have received prior intravesical chemotherapy are allowed if completed 28 days prior to cycle 1 day
Patients may have received one prior chemotherapy regimen for recurrence or progression; cisplatinum with concurrent radiation does not count as a prior chemotherapy; prior treatment with bevacizumab is allowable
Have received cancer treatment that includes chemotherapy for at least 2 months
Patients may have received any of the following therapies: surgery, chemotherapy, hormones, biologics, or radiation
Received previous chemotherapy
Subject has received chemotherapy within the past 2 weeks
Having received chemotherapy with or without radiation therapy
Subject has received chemotherapy, radiotherapy or surgery for the treatment of breast cancer
Have received radiation therapy or chemotherapy for any condition other than primary HNC
Patient must not have received chemotherapy within 3 weeks of initiation of PCI
Patients may have previously received other chemotherapy
Cancer diagnosis or received treatment (chemotherapy or radiotherapy) for malignancy within the previous 6 months
Multiple myeloma – must have received prior chemotherapy; consolidation of chemotherapy by autografting prior to nonmyeloablative HCT is permitted
Received chemotherapy for treatment of childhood cancer
Patient has received prior chemotherapy or radiotherapy for this cancer
Patients who have received any prior therapy for prostate cancer with surgery, radiation, and/or chemotherapy
Patients must not have received prior chemotherapy or radiation for >= 2 weeks before study enrollment
Patients who have received more than one previous therapy regimen (radiation or chemotherapy) are not eligible for this study
Patient has received chemotherapy for any type of cancer within 90 days from date of screening CDU;
At the time of enrollment, patients may not have received any biological, chemotherapy, or radiation therapy
Patients who have received prior chemotherapy for any abdominal or pelvic tumor are excluded; patients who have received neoadjuvant chemotherapy prior to their initial debulking are excluded; patients may have received prior adjuvant chemotherapy for breast cancer
Must not have received prior radiation therapy or chemotherapy for this diagnosis
Patients who have received previous treatment (chemotherapy or radiotherapy) for any brain tumor (primary or metastatic)
Patients may not have received prior chemotherapy or radiation therapy for lung cancer
Patient has received prior chemotherapy or radiotherapy for this cancer
Must have received at least 1 prior approved immunotherapy or chemotherapy; however, not within 28 days of the initial dose of study drug. May have received prior radiotherapy for their malignancy.